UNSPSC 51292402: Fengabine

This classification denotes an antidepressant agent with the molecular formula C17H17Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YQG0NJI5A7, chemically known as sl 79,229-00 but generally known as fengabine, which bears US NIH Compound Identifier 5362066. European Medicines Agency schedules Fengabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07563MIG.

UNSPSC 51292402 Fengabine (Commodity) encompasses pharmaceutical products and drug-delivery systems that state and local governments procure for public health and community wellness programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for emergency response and harm-reduction initiatives, as well as generic multi-source pharmaceuticals and over-the-counter products for distribution through state health systems and cooperative purchasing networks. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope reflects direct procurement of finished pharmaceutical products and related delivery systems, with vendors typically required to comply with cGMP, Drug Supply Chain Security Act standards, FDA requirements, and state-specific contracting and insurance requirements.

Activity under the code spans Florida, Texas, and Minnesota with broader participation through multistate cooperative agreements. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors typically must maintain relationships with authorized wholesalers, demonstrate pricing flexibility across multiple formats, carry substantial general liability and professional liability insurance, and comply with federal and state regulatory frameworks including potential FEMA funding compliance where applicable.